US Physicalrapy Inc (USPH) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
US Physicalrapy Inc stock (USPH) is currently trading at $74.96. US Physicalrapy Inc PE ratio is 52.01. US Physicalrapy Inc PS ratio (Price-to-Sales) is 1.45. Analyst consensus price target for USPH is $104.00. WallStSmart rates USPH as Hold.
- USPH PE ratio analysis and historical PE chart
- USPH PS ratio (Price-to-Sales) history and trend
- USPH intrinsic value — DCF, Graham Number, EPV models
- USPH stock price prediction 2025 2026 2027 2028 2029 2030
- USPH fair value vs current price
- USPH insider transactions and insider buying
- Is USPH undervalued or overvalued?
- US Physicalrapy Inc financial analysis — revenue, earnings, cash flow
- USPH Piotroski F-Score and Altman Z-Score
- USPH analyst price target and Smart Rating
US Physicalrapy Inc
📊 No data available
Try selecting a different time range
USPH Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · US Physicalrapy Inc (USPH)
USPH trades 39% above its Graham fair value of $63.28, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
US Physicalrapy Inc (USPH) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, eps growth, institutional own.. Concerns around return on equity. Fundamentals are solid but monitor weak areas for improvement.
US Physicalrapy Inc (USPH) Key Strengths (3)
108.57% of shares held by major funds and institutions
Paying $1.45 for every $1 of annual revenue
Strong earnings growth at 23.60% per year
Supporting Valuation Data
US Physicalrapy Inc (USPH) Areas to Watch (7)
Low profitability relative to shareholder equity
Paying a premium for growth, expensive relative to earnings expansion
Thin operating margins with cost pressures present
Thin profit margins with limited profitability
Small-cap company with higher risk but more growth potential
Fairly priced relative to book value
Solid revenue growth at 12.50% per year
Supporting Valuation Data
US Physicalrapy Inc (USPH) Detailed Analysis Report
Overall Assessment
This company scores 58/100 in our Smart Analysis, earning a C grade. Out of 10 metrics analyzed, 3 register as strengths (avg 8.7/10) while 7 fall into concern territory (avg 4.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Price/Sales, EPS Growth. Valuation metrics including Price/Sales (1.45) suggest the stock is attractively priced. Growth metrics are encouraging with EPS Growth at 23.60%.
The Bear Case
The primary concerns are Return on Equity, PEG Ratio, Operating Margin. Some valuation metrics including PEG Ratio (2.64), Price/Book (2.34) suggest expensive pricing. Growth concerns include Revenue Growth at 12.50%, which may limit upside. Profitability pressure is visible in Return on Equity at 7.59%, Operating Margin at 11.00%, Profit Margin at 5.12%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 7.59% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 12.50% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Institutional Own., Price/Sales) and negatives (Return on Equity, PEG Ratio). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
USPH Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
USPH's Price-to-Sales ratio of 1.45x trades 26% below its historical average of 1.97x (26th percentile). The current valuation is 68% below its historical high of 4.6x set in Aug 2018, and 77% above its historical low of 0.82x in Mar 2009. Over the past 12 months, the PS ratio has compressed from ~1.6x as trailing revenue scaled faster than the stock price.
Compare USPH with Competitors
Top MEDICAL CARE FACILITIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for US Physicalrapy Inc (USPH) · HEALTHCARE › MEDICAL CARE FACILITIES
The Big Picture
US Physicalrapy Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 773M with 13% growth year-over-year. Profit margins are thin at 5.1%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
ROE of 759.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 21M in free cash flow and 25M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can US Physicalrapy Inc push profit margins above 15% as the business scales?
Valuation compression risk at a P/E of 52.0x. Any growth miss could trigger a sharp correction.
Dividend sustainability with a current yield of 242.0%. Watch payout ratio and free cash flow coverage.
Sector dynamics: monitor MEDICAL CARE FACILITIES industry trends, competitive moves, and regulatory changes that could impact US Physicalrapy Inc.
Bottom Line
US Physicalrapy Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About US Physicalrapy Inc(USPH)
NYSE
HEALTHCARE
MEDICAL CARE FACILITIES
USA
US Physical Therapy, Inc. operates outpatient physical therapy clinics that provide preoperative and postoperative care and treatment for orthopedic-related disorders, sports-related injuries, preventive care, injured worker rehabilitation, and neurology-related injuries. The company is headquartered in Houston, Texas.